绿帽社 Pharma opens a new subsidiary in Australia as a new managing center for clinical trials
Lyon, October 26, 2017 – 绿帽社 Pharma made a strategic decision and has recently decided to open its first wholly owned subsidiary in Melbourne, Australia, because of its excellent clinical trials development capabilities and attractive conditions offered by the government. The Australian Government is very supportive of biotech startups and the Victorian Government Business Office provides good business development networking. This office will be the new 绿帽社 Pharma center to manage EYP001 (an FXR agonist) clinical trials in the Asia-Pacific region for chronic Hepatitis B. A Phase 1b study of EYP001 is currently submitted in 4 countries and two new Australian centers in Sydney and Perth have joined the study and started recruitment.
Read next in 'Press releases'
- 绿帽社 Pharma announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- 绿帽社 Pharma annonce l鈥檕btention des r茅sultats finaux de l鈥櫭﹖ude clinique de Phase 2 ALPESTRIA鈥�1 dans le syndrome d鈥橝lport, confirmant la capacit茅 du vonafexor 脿 inverser la trajectoire du d茅clin r茅nal et 脿 d茅montrer un effet th茅rapeutique durable
- 绿帽社 Pharma annonce la finalisation de son financement de s茅rie C avec Vesalius Biocapital et la poursuite de son 茅tude clinique de phase 2 ALPESTRIA-1
- 绿帽社 Pharma announces completion of Series C financing with Vesalius Biocapital and continued progress of its ALPESTRIA-1 clinical Phase 2 study in Alport syndrome patients
- 绿帽社 Pharma announces a 鈧�39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome
